Mission

To develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease.

About Us

The Canadian Cancer Trials Group is a cooperative oncology group which carries out clinical trials in cancer therapy, supportive care and prevention across Canada and internationally. It is one of the national programmes and networks of the Canadian Cancer Society Research Institute (CCSRI), and is supported by the Canadian Cancer Society (CCS).

Read More

Faculty Researchers

Meet the Faculty Researchers

Information

The information contained in this website is intended for use by Canadian Cancer Trials Group members at participating centres.

Recently Activated

  • CE7 
    Stereotactic Radiosurgery compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases
  • CE8 
    Marizomib with Standard Temozolomide-Based Radiochemotherapy vs Temozolomide-Based Radiochemotherapy Alone in Glioblastoma
  • HN9 
    Cisplatin + Rtx vs Durvalumab + Rtx followed by Durvalumab vs Durvalumab + Rtx followed by Tremelimumab and Durvalumab in HPV-Positive Oropharyngeal SCC
  • I234 
    Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol
  • MAC23 
    Hypofractionated Post-Mastectomy Rtx with Breast Reconstruction
  • OV25 
    Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women with BRCA 1/2 Mutations
  • BRC6F 
    Durvalumab + Tremelimumab in Previously Treated Anti-PD-1/PD-L1 Resistant SCLC (Lung-MAP Non-Match Sub-Study)

    • Planned Trials

  • ALC5 
    Novel Therapeutics vs Azaciticine in Patients with AML or High Risk Myelodysplastic Syndrome, Aged 60 or Older (LEAP, Intergroup Less Intense AML Platform Trial)
  • ALC6 
    Efficacy of the Addition of Inotuzumab Ozogamicin to Frontline Therapy in Young Adults with Precursor B-Cell ALL
  • BL13 
    Trimodality Therapy With/out Durvalumab to Treat Patients with Muscle-Invasive Bladder Cancer
  • BLC3 
    BCG Strain Differences and T cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-naive High-grade Non-muscle Invasive Bladder Cancer
  • CRC8 
    Nivolumab after Combined Modality Therapy in High-Risk Anal Cancer
  • CRC9 
    Circulating Tumor DNA as a Predictive Marker for Response to Chemotherapy in Pts with Stage II Colon Ca
  • LY18 
    A Phase I Master Protocol of Novel Combination Therapy for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma
  • MA39 
    Tailor RT: Trial of Regional Rtx in Biomarker Low Risk Node Positive Breast Cancer
  • PNC1 
    InPACT: International Penile Advanced Cancer Trial
  • REC4 
    Phase III RandOmized Study comparing PERioperative nivolumab vs observation in Renal Cell Carcinoma undergoing nephrectomy (PROSPER RCC)
    •